A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray
- 1.1k Downloads
A Phase I study to assess the single and multipledose pharmacokinetics (PKs) and safety and tolerability of oromucosally administered Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) spray, an endocannabinoid system modulator, in healthy male subjects.
Subjects received either single doses of THC/CBD spray as multiple sprays [2 (5.4 mg THC and 5.0 mg CBD), 4 (10.8 mg THC and 10.0 mg CBD) or 8 (21.6 mg THC and 20.0 mg CBD) daily sprays] or multiple doses of THC/CBD spray (2, 4 or 8 sprays once daily) for nine consecutive days, following fasting for a minimum of 10 h overnight prior to each dosing. Plasma samples were analyzed by gas chromatography-mass spectrometry for CBD, THC, and its primary metabolite 11-hydroxy-THC, and various PK parameters were investigated.
Δ9-Tetrahydrocannabinol and CBD were rapidly absorbed following single-dose administration. With increasing single and multiple doses of THC/CBD spray, the mean peak plasma concentration (Cmax) increased for all analytes. There was evidence of dose-proportionality in the single but not the multiple dosing data sets. The bioavailability of THC was greater than CBD at single and multiple doses, and there was no evidence of accumulation for any analyte with multiple dosing. Inter-subject variability ranged from moderate to high for all PK parameters in this study. The time to peak plasma concentration (Tmax) was longest for all analytes in the eight spray group, but was similar in the two and four spray groups. THC/CBD spray was well-tolerated in this study and no serious adverse events were reported.
The mean Cmax values (<12 ng/mL) recorded in this study were well below those reported in patients who smoked/inhaled cannabis, which is reassuring since elevated Cmax values are linked to significant psychoactivity. There was also no evidence of accumulation on repeated dosing.
KeywordsCannabidiol Cannabinoid Delta-9-tetrahydrocannabinol THC/CBD spray Spasticity Sativex Nabiximols
GW Pharma Ltd. produces THC/CBD spray and is licensed for the treatment of spasticity in multiple sclerosis in several European countries. This study was funded by GW Pharma Ltd. D. Wilbraham is an employee of Quintiles Ltd who were contracted to perform the clinical study. C. Stott, L. White, S. Wright and G. Guy are all employees of GW Pharma Ltd, and are shareholders of the company.
- 1.Richards RG, Sampson FC, Beard SM, Tappenden P (2002) A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Tech Assess 6(10):1–73Google Scholar
- 3.Rog DJ, Nurmikko TJ, Friede T, Young CA (2005) Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 8:283–291Google Scholar
- 4.Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT et al (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39(2):167–179PubMedCrossRefGoogle Scholar
- 15.Foltz RL, McGinnis KM, Chinn DM (1983) Quantitative measurement of delta 9-tetrahydrocannabinol and two major metabolites in physiological specimens using capillary column gas chromatography negative ion chemical ionization mass spectrometry. Biochemical MS 10(5):316–323Google Scholar
- 18.FDA Guidance for Industry (2001) Bioanalytical method validation issued by the U.S Department of Health and Human Services Food and Drug Administration. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf. Accessed July 2012
- 19.Miller JC, Miller JN (1992) Statistics for analytical chemistry. Ellis Horwood series in analytical chemistry. Ellis Horwood, ChichesterGoogle Scholar
- 20.Guy GW, Robson PJ (2003) A phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a Cannabis Based Medicine Extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers (GWPK0112). J Cannabis Ther 2003(3/4):79–120Google Scholar
- 21.Guy GW, Robson PJ (2003) A phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of Cannabis Based Medicine Extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK0215). J Cannabis Ther 2003(3/4):121–152Google Scholar
- 23.FDA (2004) MARINOL® (Dronabinol) clinical information. Available at: http://www.fda.gov/ohrms/dockets/dockets/05n0479/05N-0479-emc0004-04.pdf, Accessed Sept 2012